stockrow
Sunday 8 November 2026
Export IDXG’s income statement to Excel — free account
Interpace Biosciences, Inc.
IDXG
Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024.
- Revenue
- −1.09%
- EPS
- +104.1%
- Free cash flow
- −92.1%
Quarter to June 2026, against a year earlier
7.00
0.00
0.00%
Follow IDXG
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
1.18 | 0.22 | 0.36 | 0.30 |
P/S ratio |
0.10 | 0.14 | 1.19 | 1.25 | |
P/FCF ratio |
1.02 | 1.08 | 9.67 | 11.00 | |
P/Operating CF |
2.06 | 2.55 | 152.18 | 460.74 | |
P/B ratio |
0.00 | 0.24 | 1.87 | 1.94 | |
Price to Tangible BV |
0.00 | 0.24 | 1.87 | 1.94 | |
EV/Sales |
0.13 | 0.15 | 1.19 | 1.25 | |
EV/EBITDA |
1.00 | 1.16 | 10.11 | 8.90 | |
EV/Operating CF |
1.11 | 0.99 | 8.87 | 10.17 | |
EV/FCF |
1.38 | 1.15 | 9.71 | 11.04 | |
Quick Ratio |
1.24 | 1.60 | 2.16 | 1.82 | |
Current Ratio |
1.54 | 1.94 | 2.51 | 2.22 | |
Net Debt/EBITDA |
(1.04) | (1.38) | (1.96) | (4.83) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
3.21 | 1.59 | 1.51 | 1.54 | |
Operating CF/Net income |
2.13 | 0.09 | 0.39 | 0.62 | |
Capex/Depreciation |
(0.52) | (0.16) | (0.63) | (0.24) | |
Research and Development Expense of Revenue |
1.71% | 1.54% | 1.69% | 1.63% | |
Selling, General and Administrative Expense of Revenue |
47.33% | 46.88% | 51.24% | 56.76% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.08% | 0.04% | 0.04% | 0.04% | |
Graham Net Nets |
(0.80) | (0.29) | (0.01) | (0.01) | |
Graham Number |
0.00 | 125.75 | 54.54 | 50.33 | |
Earnings Yield |
84.67% | 452.12% | 276.25% | 329.25% | |
Free Cash Flow Yield |
98.23% | 92.35% | 10.34% | 9.09% | |
Revenue per Share |
9.89 | 10.43 | 1.98 | 1.65 | |
Operating CF per Share |
2.19 | 2.42 | 0.06 | 0.02 | |
Capex per Share |
(0.13) | (0.04) | (0.03) | (0.01) | |
Free Cash Flow per Share |
2.06 | 2.37 | 0.03 | 0.01 | |
Cash per Share |
1.61 | 2.83 | 0.58 | 0.49 | |
Shareholders Equity per Share |
(0.34) | 25.27 | 5.07 | 4.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.34) | 25.27 | 5.07 | 4.20 | |
Free Cash Flow |
1.82 | 2.10 | 0.14 | 0.04 | |
Working Capital |
3.19 | 4.80 | 6.00 | 6.02 | |
Capital Expenditures |
(0.12) | (0.04) | (0.14) | (0.06) | |
Net Current Asset Value |
(3.20) | (1.57) | (0.36) | (0.34) | |
EV/EBIT |
1.18 | 1.42 | 12.81 | 10.87 | |
Capex to Sales |
0.01 | 0.00 | 0.02 | 0.01 | |
Price to Operating Income |
0.87 | 1.33 | 12.75 | 10.84 | |
| Other line items | |||||
Average Receivables |
6.63 | 7.10 | 7.35 | 6.77 | |
Average Payables |
1.56 | 1.32 | 1.27 | 1.40 | |
Average Assets |
13.04 | 24.32 | 23.95 | 23.44 | |
Average Common Equity |
(28.99) | 10.07 | 11.25 | 11.02 |
Columns are period end dates · fundamentals updated 26 Oct 2026